The investigators assessed temporal changes in patterns of induction therapy, and evaluated short-term renal and survival outcomes, as well as safety outcomes, prior to and following the introduction ...

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Forty-three evaluable patients with common/pre-B (n ...

For younger, fit patients with mantle cell lymphoma (MCL), adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to standard induction therapy with bendamustine/rituximab followed by ...

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus drug ...

Even in nonproliferative class 1-2 LN, glucocorticoid monotherapy may be insufficient to prevent long-term renal damage. Combination therapy should be considered. Patients with class 1-2 lupus ...

Findings showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission, clinical response, and endoscopic improvement compared with placebo.

The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash. Having a certain laboratory abnormality may be an indicator of ...

Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study The article by Fietkau et al entitled “Benefit ...

Please provide your email address to receive an email when new articles are posted on . Concomitant use of common medications did not significantly affect treatment efficacy or safety during UC ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...